ATE476978T1 - Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns - Google Patents

Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns

Info

Publication number: ATE476978T1
Authority: AT; Austria
Prior art keywords: brain; glucose utilization; nervous system; central nervous; agents
Prior art date: 1998-12-17

Application number

AT99966359T

Other languages

English (en)

Inventor

Daniel G Chain

Mike Cawthorne

Original Assignee

Mindset Biopharmaceuticals Usa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-17

Filing date

1999-12-17

Publication date

2010-08-15

1999-12-17 Application filed by Mindset Biopharmaceuticals Usa filed Critical Mindset Biopharmaceuticals Usa

2010-08-15 Application granted granted Critical

2010-08-15 Publication of ATE476978T1 publication Critical patent/ATE476978T1/de

Links

210000004556 brain Anatomy 0.000 title abstract 5
206010022489 Insulin Resistance Diseases 0.000 title 1
230000003923 mental ability Effects 0.000 title 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 4
239000003795 chemical substances by application Substances 0.000 abstract 4
239000008103 glucose Substances 0.000 abstract 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 4
210000003169 central nervous system Anatomy 0.000 abstract 3
102000004877 Insulin Human genes 0.000 abstract 2
108090001061 Insulin Proteins 0.000 abstract 2
102000000536 PPAR gamma Human genes 0.000 abstract 2
108010016731 PPAR gamma Proteins 0.000 abstract 2
229940125396 insulin Drugs 0.000 abstract 2
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 abstract 2
208000000044 Amnesia Diseases 0.000 abstract 1
206010012289 Dementia Diseases 0.000 abstract 1
229940122355 Insulin sensitizer Drugs 0.000 abstract 1
208000026139 Memory disease Diseases 0.000 abstract 1
229940123464 Thiazolidinedione Drugs 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
125000002015 acyclic group Chemical group 0.000 abstract 1
230000008499 blood brain barrier function Effects 0.000 abstract 1
210000001218 blood-brain barrier Anatomy 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000006984 memory degeneration Effects 0.000 abstract 1
208000023060 memory loss Diseases 0.000 abstract 1
229960005095 pioglitazone Drugs 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
108091006084 receptor activators Proteins 0.000 abstract 1
150000001467 thiazolidinediones Chemical class 0.000 abstract 1
-1 troglitazone Chemical class 0.000 abstract 1
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 abstract 1
229960001641 troglitazone Drugs 0.000 abstract 1
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F42—AMMUNITION; BLASTING
- F42C—AMMUNITION FUZES; ARMING OR SAFETY MEANS THEREFOR
- F42C15/00—Arming-means in fuzes; Safety means for preventing premature detonation of fuzes or charges
- F42C15/24—Arming-means in fuzes; Safety means for preventing premature detonation of fuzes or charges wherein the safety or arming action is effected by inertia means
- F42C15/26—Arming-means in fuzes; Safety means for preventing premature detonation of fuzes or charges wherein the safety or arming action is effected by inertia means using centrifugal force

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)

AT99966359T 1998-12-17 1999-12-17 Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns ATE476978T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US11266998P	1998-12-17	1998-12-17
US12225899P	1999-02-24	1999-02-24
PCT/US1999/030066 WO2000035437A2 (en)	1998-12-17	1999-12-17	Improving mental performance by increasing brain insulin sensitivity

Publications (1)

Publication Number	Publication Date
ATE476978T1 true ATE476978T1 (de)	2010-08-15

Family

ID=26810226

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99966359T ATE476978T1 (de)	1998-12-17	1999-12-17	Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns

Country Status (8)

Country	Link
EP (1)	EP1140081B1 (de)
JP (1)	JP2002532416A (de)
AT (1)	ATE476978T1 (de)
AU (3)	AU2192000A (de)
CA (1)	CA2355645A1 (de)
DE (1)	DE69942672D1 (de)
IL (2)	IL143768A0 (de)
WO (1)	WO2000035437A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0030845D0 (en) *	2000-12-18	2001-01-31	Smithkline Beecham Plc	Novel treatment
WO2003053926A1 (en)	2001-12-13	2003-07-03	Ajinomoto Co.,Inc.	Novel phenylalanine derivative
US6716842B2 (en)	2002-04-05	2004-04-06	Warner-Lambert Company, Llc	Antidiabetic agents
EA200800879A1 (ru) *	2005-09-22	2008-10-30	ЭсБи ФАРМКО ПУЭРТО РИКО ИНК.	Агонисты ppar гамма для улучшения когнитивной функции у apoe4 отрицательных пациентов
US20100305204A1 (en) *	2007-05-24	2010-12-02	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.	Composition useful for the prevention of adverse effect due to the use of ppar-gamma agonists
US20100152249A1 (en) *	2008-12-11	2010-06-17	Board Of Trustees Of The Leland Stanford Junior University	Compositons and method for treatment of mood and cognitive impairments
EP2582368B1 (de) *	2010-06-16	2018-05-09	Alfasigma S.p.A.	Acetyl-L-carnitin zur Erhöhung der Neurogenese in neuronalem Gewebe
JP6735224B2 (ja)	2016-01-28	2020-08-05	花王株式会社	アストロサイトのグルコース代謝活性化剤
US12310967B2 (en)	2017-12-21	2025-05-27	Gliapharm Sa	Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
US12274703B2 (en)	2017-12-21	2025-04-15	Gliapharm Sa	Compositions and methods of treatment for neurological disorders comprising a dementia
WO2020132378A2 (en)	2018-12-22	2020-06-25	Gliapharm Sa	Compositions and methods of treatment for neurological disorders comprising depression

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4540564A (en) *	1982-05-18	1985-09-10	University Of Florida	Brain-specific drug delivery
US5039794A (en) *	1986-09-19	1991-08-13	Otsuka Pharmaceutical Co., Ltd.	Tumor egress factor and processes for producing the same
IT1260155B (it) *	1992-08-03	1996-03-28	Fidia Spa	Uso terapeutico della fosforil-l-serina-n-acil-sfingosina
GB9604242D0 (en) *	1996-02-28	1996-05-01	Glaxo Wellcome Inc	Chemical compounds
EP1124807A1 (de) *	1997-10-27	2001-08-22	Dr. Reddy's Research Foundation	Heterocyclische verbindungen und ihre verwendung als arzneimittel, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen
WO1999038850A1 (en) *	1998-01-29	1999-08-05	Dr. Reddy's Research Foundation	Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them
JP2002507543A (ja) *	1998-05-27	2002-03-12	ドクター・レディーズ・リサーチ・ファウンデーション	二環系化合物、その製造方法およびそれらを含有する薬学的組成物
GB9822473D0 (en) *	1998-10-16	1998-12-09	Glaxo Group Ltd	Chemical compounds
EP1123297A1 (de) *	1998-10-21	2001-08-16	Novo Nordisk A/S	Verbindungen, ihre herstellung und verwendung
WO2000023416A1 (en) *	1998-10-21	2000-04-27	Novo Nordisk A/S	New compounds, their preparation and use
AU6190199A (en) *	1998-10-21	2000-05-08	Dr. Reddy's Research Foundation	New compounds, their preparation and use
EP1123269A1 (de) *	1998-10-21	2001-08-16	Novo Nordisk A/S	Neuartige verbindungen, ihre herstellung und ihre verwendung
WO2000023445A1 (en) *	1998-10-21	2000-04-27	Novo Nordisk A/S	New compounds, their preparation and use
US6028088A (en) *	1998-10-30	2000-02-22	The University Of Mississippi	Flavonoid derivatives
US6191154B1 (en) *	1998-11-27	2001-02-20	Case Western Reserve University	Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases

1999
- 1999-12-17 AT AT99966359T patent/ATE476978T1/de not_active IP Right Cessation
- 1999-12-17 AU AU21920/00A patent/AU2192000A/en not_active Abandoned
- 1999-12-17 CA CA002355645A patent/CA2355645A1/en not_active Abandoned
- 1999-12-17 EP EP99966359A patent/EP1140081B1/de not_active Expired - Lifetime
- 1999-12-17 DE DE69942672T patent/DE69942672D1/de not_active Expired - Lifetime
- 1999-12-17 WO PCT/US1999/030066 patent/WO2000035437A2/en not_active Ceased
- 1999-12-17 IL IL14376899A patent/IL143768A0/xx active IP Right Grant
- 1999-12-17 JP JP2000587758A patent/JP2002532416A/ja active Pending
2001
- 2001-06-14 IL IL143768A patent/IL143768A/en not_active IP Right Cessation
2005
- 2005-03-23 AU AU2005201243A patent/AU2005201243A1/en not_active Abandoned
2009
- 2009-01-23 AU AU2009200266A patent/AU2009200266A1/en not_active Abandoned

Also Published As

Publication number	Publication date
IL143768A (en)	2008-04-13
AU2005201243A1 (en)	2005-04-21
WO2000035437A3 (en)	2000-11-09
IL143768A0 (en)	2002-04-21
EP1140081A2 (de)	2001-10-10
CA2355645A1 (en)	2000-06-22
EP1140081B1 (de)	2010-08-11
JP2002532416A (ja)	2002-10-02
AU2009200266A1 (en)	2009-02-19
DE69942672D1 (de)	2010-09-23
AU2192000A (en)	2000-07-03
WO2000035437A2 (en)	2000-06-22

Similar Documents

Publication	Publication Date	Title
Tarsy et al.	1974	Physostigmine in choreiform movement disorders
DE69942672D1 (de)	2010-09-23	Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns
DE69930739D1 (de)	2006-05-18	Transdermale verwendung von sekretin zur behandlung von autismus
DE3687501D1 (de)	1993-02-25	Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eines arneimittels zur behandlung von komplikationen bei diabetes mellitus.
ATE202076T1 (de)	2001-06-15	Ester der 5-aminolevulinsäure als mittel zur photosensibilisierung in der chemotherapie
DE69519099D1 (de)	2000-11-16	Aromatische aminoether als schmerzlindernde mittel
RU93055137A (ru)	1996-05-20	Гетероцикло-циклические производные аминов, способ получения, промежуточные соединения, фармацевтическая композиция, способ лечения
DK0665749T3 (da)	2000-08-28	Sammensætning til behandling af Parkinsons sygdom
IE41374B1 (en)	1979-12-19	A composition for treating schizophrenia
AU2016204334B2 (en)	2018-03-15	Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
Mertens	1990	Long-term treatment of chronic schizophrenia patients with risperidone
HUT45983A (en)	1988-09-28	Process for production of derivatives of imidazolidinone
Boller et al.	1989	Alzheimer's disease and THA: a review of the cholinergic theory and of preliminary results
DE59602626D1 (de)	1999-09-09	Neuartig substituierte dtpa-derivate, deren metallkomplexe, diese komplexe enthaltende pharmazeutische mittel, deren verwendung in der diagnostik und therapie, sowie verfahren zur herstellung der komplexe und mittel
ATE162718T1 (de)	1998-02-15	Verwendung von prostacyclin-derivaten zur verhinderung oder behandlung von störungen der mikrozirkulation bei gabe von röntgen-, nmr- oder ultraschallkontrastmitteln
KR870007937A (ko)	1987-09-23	2β-치환된 티오 메틸페니실린 유도체 및 그의 제조방법 및 용도
Davidoff et al.	1978	Enhancement of the mitochondrial Ca2+ uptake rate by phenethylbiguanide and other organic cations with hypoglycemic activity
JP2002532416A5 (ja)	2007-02-08	脳のグルコース利用を増進させる医薬組成物
KR880009944A (ko)	1988-10-06	피페라진 카르복실산, 그의 제조방법 및 그를 함유하는 약학적 조성물
Cotzias	1969	L-Dopa in Parkinson's disease
Cahn et al.	1957	Observations on the Clinical Effects of a new Tranquillizing Agent in Psychotic Conditions
FANN	1973	Some clinically important interactions of psychotropic drugs
EP0255704A3 (de)	1988-10-05	Pyridazinon-Derivate, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
DE3778642D1 (de)	1992-06-04	Therapeutikum zur behandlung von magengeschwueren.
JPS59193891A (ja)	1984-11-02	リフアマイシン誘導体及びその製造方法並びに該誘導体を含有する医薬

Legal Events

Date	Code	Title	Description
2011-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties